Abstract

Aim: Glomerular diseases (GD) associated with malignancies (AM, GDAM) have unique features, which are important to recognize, in the light of the progress made in cancer therapy. We aimed to describe the clinical and histopathological characteristics of patients with GDAM in relation to the presence of circulating autoantibodies, pointing to potential immune pathogenic pathways connecting cancer to GD. Materials and Methods: The included patients were studied retrospectively on the basis of a kidney biopsy proving GD and a related biopsy to establish the diagnosis of AM. We recorded patients’ demographics, serological and laboratory parameters, histopathological findings, and the type of malignancy, GD, and therapy. Results: In total, 41 patients with GDAM, with a mean age of 63.1 (±10.7) years, were studied. In 28 (68.3%) cases, GD was associated with a solid tumor, and in 13 (31.7%) patients with a lymphoid malignancy. The most frequent histopathological pattern was membranous nephropathy (43.9%). Overall, at the time of GD diagnosis, 17% of the patients were positive for antinuclear antibodies (ANA), and 12.2% for antineutrophil cytoplasmic autoantibodies (ANCA), all against myeloperoxidase (MPO). In addition, 93.3% of the patients who had membranous nephropathy were negative for transmembrane glycoprotein M-type phospholipase A2 receptor (PLA2R) antibody. Sixteen patients (39.0%) presented with acute nephritic syndrome, of whom five (31.25%) developed rapidly progressive glomerulonephritis. In a mean follow-up time of 36.1 (±28.3) months, nine (21.95%) patients ended up with end-stage kidney disease, and eight (19.5%) died. Conclusion: We found that 3.2% of patients who underwent a native kidney biopsy in our institution during the past decade, for any reason, were identified as having some type of GD associated with a malignancy. Serology indicated a significant presence of ANA or MPO-ANCA antibodies in patients with nephritic syndrome and the absence of PLA2R antibodies in patients with membranous nephropathy.

Highlights

  • Glomerular diseases (GD) represent certain patterns of injury of the glomeruli, which may be associated with an inherited or acquired disorder and manifest with various clinical pictures and grades of severity, from asymptomatic urinary abnormalities to acute kidney insufficiency

  • GD associated with malignancies (GDAM) represent a rare, secondary form of glomerular lesion and a complication of cancer, which remains a challenge for both nephrologists and oncologists

  • We retrospectively reviewed the medical records of all patients who were diagnosed with any type of GDAM in the period 2008–2018 in our hospital

Read more

Summary

Introduction

Glomerular diseases (GD) represent certain patterns of injury of the glomeruli, which may be associated with an inherited or acquired disorder and manifest with various clinical pictures and grades of severity, from asymptomatic urinary abnormalities to acute kidney insufficiency. GD associated with malignancies (GDAM) represent a rare, secondary form of glomerular lesion and a complication of cancer, which remains a challenge for both nephrologists and oncologists. They are not directly related to the tumor burden, invasion, or metastasis but are assumed to be caused by tumor cell products, such as hormones, growth factors, cytokines, and tumor antigens [1]. The pathogenic mechanisms of many glomerular lesions seem to be related to the altered immune responses associated with malignancies and, may facilitate the identification of biomarkers and the investigation of the pathology [2]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call